clinically relevant concentrations.
-- Abstract 571: Modulation of JAK2 signaling pathways in vitro and in
vivo by SGI-1252, a small molecule JAK2 inhibitor.
Conference Call Information
SuperGen will host a conference call to discuss the 2008 third quarter financial results today at 1:30 p.m. PT / 4:30 p.m. ET. The webcast will be accessible via the Investor Relations section of the Company's Web site at http://www.supergen.com. A webcast replay of the live conference call will be available shortly following the event. Alternatively, you may access a replay of the conference call by dialing 1-888-286-8010 (domestic) and 1-617-801-6888 (international); replay passcode number is 37633541. The webcast replay and conference call replay will be available for 90 days.
Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.
This press release contains "forward-looking" statements within the
meaning of Section 21A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, and is
subject to the safe harbor created thereby. The actual results could differ
materially from those projected in the forward-looking statements as a
result of a number of risks and uncertainties. These forward-looking
statements include statements regarding SuperGen's expectation that it will
receive the balance of the purchase price for Nipent from Mayne Pharma,
expectations regarding the various abilities of MP-470,
|SOURCE SuperGen, Inc.|
Copyright©2008 PR Newswire.
All rights reserved